Stevens-Johnson Syndrome (SJS) Malpractice Lawyer New York

What Is Stevens-Johnson Syndrome (SJS)?

Stevens-Johnson Syndrome is a severe, life-threatening mucocutaneous reaction — a reaction that affects both the skin and mucous membranes (eyes, mouth, genitals, respiratory tract). SJS is characterized by:

- Flu-like prodrome: Fever, sore throat, fatigue — often mistaken for a viral illness. - Mucosal involvement: Painful blisters and erosions on the lips, mouth, throat, eyes, genitals, and other mucous membranes. - Skin lesions: A rash that progresses to blisters — and then to skin detachment (epidermal necrolysis). The skin literally peels off in sheets. - Systemic involvement: SJS can affect internal organs — including the lungs, liver, kidneys, and gastrointestinal tract.

SJS is a medical emergency requiring immediate hospitalization — often in a burn ICU. The mortality rate for SJS is approximately 10%, and for TEN (the more severe form), it can be 30% or higher.

SJS is almost always caused by medications — though infections (particularly Mycoplasma pneumoniae) can also cause it. In adults, medications are the cause in over 95% of cases.

SJS vs. TEN: Understanding the Spectrum

SJS and TEN are actually part of a spectrum of the same disease — differentiated by the percentage of skin detachment:

• SJS: Less than 10% of body surface area (BSA) skin detachment.
• SJS/TEN overlap: 10-30% of BSA skin detachment.
• TEN (Toxic Epidermal Necrolysis): More than 30% of BSA skin detachment — the most severe form, with mortality rates of 30% or higher.

Medications That Cause SJS and TEN

While many medications can cause SJS, certain drugs are high-risk and are responsible for the majority of cases:

• Anticonvulsants (anti-seizure medications): Including carbamazepine (Tegretol), lamotrigine (Lamictal), phenytoin (Dilantin), and phenobarbital. These are among the most common causes of SJS. Patients of Asian descent carrying the HLA-B*1502 allele are at particularly high risk — and should be tested before starting carbamazepine.
• Allopurinol: A medication for gout — one of the most common causes of SJS, particularly at higher doses. Patients of Asian descent carrying the HLA-B*5801 allele are at particularly high risk.
• Antibiotics: Particularly sulfonamides (Bactrim/Septra/sulfamethoxazole-trimethoprim), but also penicillins, cephalosporins, and fluoroquinolones. [Link to: /medication-errors/antibiotic-delays-sepsis]
• NSAIDs: Non-steroidal anti-inflammatory drugs — particularly oxicam NSAIDs (like piroxicam) and other NSAIDs.
• Nevirapine: An antiretroviral medication used for HIV.
• Other medications: Including some chemotherapy agents, anti-gout medications, and others.

How SJS Malpractice Occurs

SJS malpractice can occur through several mechanisms:

• Failure to warn: Not warning the patient about the symptoms of SJS when prescribing a high-risk medication. The standard of care requires informing patients taking high-risk medications to watch for rash, fever, or mucosal involvement — and to stop the medication and seek immediate medical attention if these occur. [Link to: /surgical-errors/informed-consent]
• Failure to recognize early SJS symptoms: Not recognizing the early signs of SJS — flu-like symptoms, rash, mucosal involvement — when the patient presents for evaluation. SJS is often initially misdiagnosed as a viral rash, drug eruption, or flu. [Link to: /misdiagnosis/differential-diagnosis]
• Failure to stop the offending medication: Continuing the medication after SJS symptoms develop — or failing to identify and stop the offending drug. The most critical intervention in SJS is immediate discontinuation of the offending medication — and every day of delay worsens the outcome.
• Failure to refer for specialized care: Not referring the patient to a specialized burn unit or intensive care — SJS patients require specialized care, similar to burn victims.
• Prescribing a high-risk medication when a safer alternative was available: Prescribing a high-risk medication (like carbamazepine or allopurinol) without testing for high-risk alleles (like HLA-B*1502 or HLA-B*5801) in patients of Asian descent — or without trying safer alternatives first.
• Failure to perform genetic testing: Not performing recommended genetic testing (HLA-B*1502 for carbamazepine, HLA-B*5801 for allopurinol) in high-risk populations before prescribing these medications.
• Re-exposure: Re-prescribing a medication that previously caused an SJS reaction in the same patient — this is catastrophic and almost always negligent.

Recognizing Early SJS Symptoms

Early recognition of SJS is critical — as immediate discontinuation of the offending medication can prevent progression to severe disease. The standard of care requires healthcare providers to recognize the early signs:

• Flu-like prodrome: Fever, sore throat, fatigue, malaise — often appearing 1-3 days before the rash. This is often the first sign — and is frequently dismissed as a viral illness.
• Mucosal involvement: Painful blisters and erosions on the lips, mouth, throat, eyes, and genitals. This is a red flag that should immediately raise suspicion for SJS.
• Skin rash: A rash that typically starts on the face and chest — and progresses to blisters. The rash often has a target appearance (round lesions with a dark center, pale ring, and outer red ring).
• Skin pain: Severe skin pain or tenderness — out of proportion to the visible rash. This is an important distinguishing feature — SJS skin is painful, while many other rashes are itchy.
• Eyes: Redness, pain, tearing, and light sensitivity — early eye involvement can progress to permanent blindness if not treated.
• Progression to skin detachment: The rash progresses to blisters — and then to skin peeling off in sheets. This is a medical emergency requiring immediate hospitalization.

The Standard of Care for SJS

The standard of care for SJS is established by dermatology and burn medicine guidelines. Key elements include:

1. Early recognition: Healthcare providers must maintain a high index of suspicion for SJS in patients who develop rash, fever, and mucosal involvement — particularly if they are taking a high-risk medication.

2. Immediate discontinuation of the offending medication: The most critical intervention. Every day of delay worsens the outcome. If multiple medications are being taken, all recently started medications should be stopped (if possible).

3. Immediate referral for specialized care: SJS patients require specialized care — often in a burn ICU. The standard of care is to transfer the patient to a facility with burn unit capabilities for severe cases.

4. Supportive care: Including fluid management (similar to burn victims), wound care, pain management, nutritional support, and prevention of infection.

5. Ophthalmology consultation: Immediate ophthalmology consultation is required — as eye involvement can rapidly progress to permanent blindness. [Link to: /surgical-errors/eye-surgery-malpractice]

6. No re-exposure: The offending medication must never be re-prescribed to the patient — and the patient should be educated about their allergy and given documentation for future medical care.

7. Genetic testing (for prevention): For high-risk medications (carbamazepine, allopurinol) in high-risk populations — the standard of care includes genetic testing (HLA-B*1502, HLA-B*5801) before prescribing.

Consequences of SJS and TEN

The consequences of SJS and TEN can be devastating and lifelong:

• Permanent blindness: Eye involvement is one of the most feared complications — SJS can cause permanent corneal damage, scarring, and blindness, even with treatment. [Link to: /surgical-errors/eye-surgery-malpractice]
• Skin scarring and disfigurement: Severe skin detachment causes scarring — which can be disfiguring, particularly on the face and hands.
• Chronic eye problems: Including dry eyes, corneal erosions, and visual impairment — requiring lifelong ophthalmologic care.
• Respiratory damage: Mucosal involvement in the respiratory tract can cause strictures, chronic lung disease, and respiratory failure.
• Gastrointestinal damage: Mucosal involvement in the GI tract can cause strictures, adhesions, and chronic GI problems.
• Genital scarring: Mucosal involvement in the genitals can cause strictures, adhesions, and sexual dysfunction.
• Organ damage: SJS can affect the liver, kidneys, lungs, and other organs — causing permanent damage.
• Infection and sepsis: Loss of skin integrity makes patients vulnerable to infection — which can progress to sepsis and death. [Link to: /medical-malpractice/sepsis-malpractice]
• Death: SJS mortality is approximately 10%, and TEN mortality is 30% or higher.
• Psychological trauma: The experience of SJS — with severe pain, disfigurement, and prolonged hospitalization — causes significant psychological trauma.

Proving Causation in SJS Cases

Proving that medical negligence caused or worsened SJS requires establishing:

1. The medication caused the SJS: Expert testimony (from a dermatologist, allergist, or pharmacologist) identifying the offending medication — based on the timeline of drug exposure and symptom onset.

2. The standard of care was breached: Expert testimony that the provider failed to warn about SJS symptoms, failed to recognize early SJS, failed to stop the medication promptly, failed to refer for specialized care, or failed to perform genetic testing.

3. The breach worsened the outcome: Expert testimony that prompt discontinuation of the medication, early recognition, or proper referral would have reduced the severity of SJS — and that the delay caused additional harm (more extensive skin detachment, permanent blindness, or death).

The defense may argue that SJS is an unpredictable reaction, that the patient's genetics were the primary cause, or that the outcome was inevitable. Expert testimony is required to counter these arguments — and to show that the standard of care was breached and that the breach worsened the outcome.

New York Statute of Limitations

Under CPLR § 214-a, the statute of limitations for SJS malpractice is 2.5 years from the date of the negligent act — typically the date the provider failed to recognize SJS, failed to stop the medication, or failed to refer for specialized care. The continuous treatment doctrine may extend the deadline if you continued receiving treatment from the same provider for SJS. For wrongful death (if the patient died from SJS), the deadline is 2 years from the date of death (EPTL § 5-4.1). [Link to: /medication-errors/statute-of-limitations] [Link to: /wrongful-death/statute-of-limitations]

Frequently Asked Questions

The value of a medical malpractice case in New York depends on several factors, including the severity of the injury, the strength of liability evidence, and the economic and non-economic damages involved. New York is one of the few states with no caps on medical malpractice damages, meaning there is no artificial limit on what you can recover. Below are typical settlement ranges based on injury severity.